论文部分内容阅读
目的:探讨氨磺必利与舒必利治疗精神分裂症的临床疗效和安全性。方法将100例精神分裂症患者随机分为两组,每组50例,研究组口服氨磺必利治疗,对照组口服舒必利治疗,观察8周。采用阳性与阴性症状量表评定临床疗效,副反应量表评定不良反应。结果治疗8周末研究组总有效率90.0%,对照组为84.0%,两组总有效率比较差异无显著性(χ2=0.80, P>0.05);研究组不良反应发生率为16.0%,对照组为52.0%,研究组不良反应发生率显著低于对照组(χ2=14.44,P<0.01)。结论氨磺必利与舒必利治疗精神分裂症疗效显著,总体疗效相当,但氨磺必利治疗不良反应轻微,安全性高,依从性好。“,”Objective To explore the efficacy and safety of amisulpride and sulpiride in the treatment of schizophrenia .Methods A total of 100 schizophrenia patients were randomly divided into two groups of 50 ones each ,research group took orally amisulpride and control group did sulpiride for 8 weeks .Clinical effi-cacies were assessed with the Positive and Negative Syndrome Scale (PANSS) and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results Total effective rate was respectively 90 .0% in research and 84 .0% in control group at the end of the 8th week ,which showed no significant group differ-ence (χ2 =0 .80 , P> 0 .05);the incidence of adverse reaction was respectively 16 .0% in research and 52 .0% in control group ,the former was significantly lower than the latter (χ2 =14 .44 , P<0 .01) .Con-clusion Both amisulpride and sulpiride an equivalent evident effect on schizophrenia ,but amisulpride has mild adverse reactions ,higher safety and better compliance .